November 07, 2024
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 06, 2024
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
November 06, 2024
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
November 06, 2024
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
November 06, 2024
MOMA Therapeutics to Participate in Upcoming Investor Conferences
November 06, 2024
Flare Therapeutics to Present at Two Upcoming November Conferences
November 05, 2024
Revolution Medicines to Participate in Upcoming Investor Conferences
November 05, 2024
CARGO Therapeutics to Participate in Upcoming Investor Conferences
November 05, 2024
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity
November 04, 2024
Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference
November 04, 2024
Arvinas to Participate in Upcoming Investor Conferences
November 04, 2024
Alumis to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
October 30, 2024
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
October 28, 2024
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
October 28, 2024
Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platform
October 25, 2024
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
October 24, 2024
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
October 24, 2024
ITM, TUM, and TUM University Hospital Sign New Framework Agreement to Advance Innovative Radiopharmaceutical Cancer Treatments
October 24, 2024
Bruce Power and partners celebrate two years of commercial production of cancer-fighting isotopes
October 23, 2024
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET
October 23, 2024
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
October 23, 2024
PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial
October 23, 2024
MOMA-313 is a potent, selective Polθ inhibitor that enhances response to PARP inhibition in HR-deficient tumor models
October 23, 2024
Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium
October 23, 2024
Atavistik Bio Presents Preclinical Data on Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor, at EORTC-NCI-AACR Symposium
October 23, 2024
Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals
October 22, 2024
Exo Therapeutics Announces Late Breaking Poster at American College of Rheumatology’s Convergence (ACR)
October 22, 2024
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
October 21, 2024
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
October 21, 2024
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
October 18, 2024
Actineer, a Joint Venture of ITM and CNL, Begins Actinium-225 Production
October 18, 2024
ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a Manufacturing and Supply Agreement for n.c.a. Lutetium-177
October 17, 2024
Saugeen Ojibway Nation, Bruce Power, Isogen and ITM double down on production of cancer-fighting medical isotopes
October 15, 2024
Circle Pharma announces first patients dosed in Phase 1 clinical trial of first-in-class oral Cyclin A/B RxL inhibitor CID-078 for advanced solid tumors
October 15, 2024
Attovia Therapeutics Appoints Chief Financial Officer
October 15, 2024
Atavistik Bio Announces Nomination of Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor
October 15, 2024
Alpha-9 Oncology Appoints Jean-Jacques Bienaimé and Dr. Steven Stein to its Board of Directors
October 14, 2024
Boundless Bio Announces Departure of Chief Financial Officer
October 11, 2024
Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)
October 09, 2024
Boehringer Ingelheim and Circle Pharma announce new research collaboration to develop a novel precision cancer treatment
October 08, 2024
Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended to Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer
October 08, 2024
Bayer and MOMA Therapeutics enter collaboration and license agreement in Oncology
October 07, 2024
Revolution Medicines to Deliver Multiple Presentations at the 2024 EORTC-NCI-AACR Symposium and Host Investor Webcast
October 04, 2024
A2 Bio to Present Safety and Biomarker Data from EVEREST-1 Trial during 2024 Annual Meeting of the Society for Immunotherapy of Cancer
September 27, 2024
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
September 19, 2024
ITM to Present at Upcoming Radiopharmaceutical Investor Conferences in New York City
September 16, 2024
Circle Pharma expands leadership team to drive the development of its pipeline of oral macrocycle therapies
September 15, 2024
Scorpion Therapeutics Presents Initial Clinical Data from Its Phase 1/2 Trial of STX-478 Demonstrating Potentially Best-in-Class Mutant-Selective PI3Kα Inhibition for the Treatment of Advanced Solid Tumors at ESMO Congress 2024
September 12, 2024
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
September 11, 2024
Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference
September 11, 2024
Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024
Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer
September 09, 2024
Circle Pharma announces preclinical data poster presentation of CID-078, a first-and-only-in-class Cyclin A/B RxL inhibitor at the 2024 World Conference on Lung Cancer
September 03, 2024
Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies
September 03, 2024
Alumis to Participate in Upcoming September Investor Conferences
August 29, 2024
Arvinas to Participate in Upcoming Investor Conferences
August 28, 2024
Tango Therapeutics to Participate in Upcoming Investor Conferences
August 19, 2024
Scorpion Therapeutics to Present STX-478 Initial Phase 1/2 Data at ESMO Congress 2024
August 19, 2024
MOMA Therapeutics Announces Initiation of Phase 1 Clinical Trial for MOMA-313, a Novel Polymerase Theta Helicase Inhibitor
August 13, 2024
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
August 12, 2024
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results
August 12, 2024
Atavistik Bio Strengthens Leadership Team with Appointment of Paul Bruno, Ph.D. as Chief Business Officer
August 07, 2024
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
August 07, 2024
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
August 07, 2024
Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights
August 07, 2024
IDRx Announces $120 Million Series B Financing to Advance Potential Best-in-class New Treatment for Gastrointestinal Stromal Tumor (GIST)
August 05, 2024
Fierce Biotech Names Tubulis a “Fierce 15” Biotech Company of 2024
July 31, 2024
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
July 30, 2024
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
July 29, 2024
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
July 11, 2024
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
July 10, 2024
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
July 09, 2024
Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors
July 08, 2024
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
July 02, 2024
Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)
July 02, 2024
A Novel Exosite Inhibitor that Selectively Reprograms TBK1-STING Pathway for Autoimmune Diseases
July 01, 2024
Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors
June 27, 2024
Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer
June 27, 2024
Alumis Announces Pricing of Initial Public Offering
June 25, 2024
MOMA Therapeutics Appoints Marc Ballas, M.D., as Head of Clinical Development, and Adam Thomas as Chief People & Experience Officer
June 24, 2024
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
June 21, 2024
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
June 20, 2024
Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma
June 20, 2024
ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth
June 20, 2024
Exo Therapeutics Presents Key Data at FOCIS 2024 Demonstrating the Efficacy of Potent and Selective Exosite-targeted TBK1/STING Inhibitor in Multiple Preclinical Models
June 17, 2024
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
June 06, 2024
ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing
June 05, 2024
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
June 03, 2024
IDRx Reports Updated Preliminary Phase 1 Data from Ongoing Phase 1/1b StrateGIST 1 Trial Supporting Best-in-Class Potential for IDRX-42 in Patients with GIST
June 03, 2024
Flare Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
Arvinas to Participate in Upcoming Investor Conferences
May 29, 2024
A2 Bio Highlights Progress of CAR T-Cell Clinical Programs in Three Poster Presentations during the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
May 28, 2024
CARGO Therapeutics to Participate in Upcoming Investor Conferences
May 28, 2024
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
May 28, 2024
Saugeen Ojibway Nation, Bruce Power, Isogen and ITM advance initiative to double capacity of IPS to produce cancer-fighting medical isotopes
May 23, 2024
Tango Therapeutics Announces Discontinuation of TNG348 Program
May 23, 2024
Tyra Biosciences to Present at Upcoming Investor Conferences
May 23, 2024
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
May 16, 2024
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
May 16, 2024
A2 Bio Announces First Patient Dosed in EVEREST-2 Phase 1 Clinical Trial of Novel Mesothelin Logic-Gated CAR T
May 14, 2024
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer
May 13, 2024
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
May 09, 2024
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
May 09, 2024
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 09, 2024
Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives
May 08, 2024
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
May 08, 2024
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 07, 2024
Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors
May 07, 2024
ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer
May 07, 2024
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 06, 2024
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
May 06, 2024
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
May 02, 2024
Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer
May 02, 2024
Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines: Activation Lethality
May 02, 2024
Arvinas to Present at Upcoming Investor Conferences
May 02, 2024
Alpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3202 in Patients with Locally Advanced or Metastatic Melanoma
May 01, 2024
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
April 30, 2024
Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005
April 24, 2024
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
April 24, 2024
A2 Bio to Highlight Progress of CAR T Clinical Programs in Three Poster Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2024
ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial
April 23, 2024
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
April 15, 2024
CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
April 11, 2024
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
April 11, 2024
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
April 09, 2024
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
April 09, 2024
Flare Therapeutics Presents Data at AACR 2024 Annual Meeting Characterizing PPARG-Derived Immune Cell Patterns in Urothelial Cancer Patients After Anti-PD1 Therapy
April 08, 2024
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
April 08, 2024
Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024
April 08, 2024
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
April 08, 2024
Exploring the Use of Molecules that Stabilize the Interaction between LRRK2 Kinase and the 14-3-3 Adapter Protein as a Neuroprotective Therapy for Parkinson’s Disease
April 04, 2024
Revolution Medicines to Participate in Upcoming Investor Conferences
April 01, 2024
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
March 27, 2024
IDRx Appoints David P. Kerstein, M.D., as Chief Medical Officer
March 27, 2024
Boundless Bio Announces Pricing of Initial Public Offering
March 25, 2024
A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors
March 21, 2024
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 19, 2024
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
March 18, 2024
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
March 18, 2024
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
March 14, 2024
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline
March 12, 2024
IDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBO
March 11, 2024
Synnovation Therapeutics Announces First Patient Dosed in Phase I Trial with SNV1521, a PARP1 Selective Inhibitor for the Treatment of Solid Tumors
March 11, 2024
Alumis to Participate in the 2024 Leerink Partners Global Biopharma Conference
March 09, 2024
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting
March 06, 2024
Tango Therapeutics to Participate in Upcoming Investor Conferences
March 06, 2024
Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
March 05, 2024
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 05, 2024
Flare Therapeutics to Present Immune Profiling Data from Urothelial Cancer Patients Treated with Anti-PD1 Therapy at AACR 2024 Annual Meeting
March 05, 2024
Boundless Bio Announces Multiple Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024
March 04, 2024
Arvinas to Participate in Upcoming Investor Conferences
March 04, 2024
A2 Bio Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530 in Colorectal Cancer
March 01, 2024
https://www.businesswire.com/news/home/20240301890988/en/FogPharma-Announces-145-Million-Financing-to-Support-Ongoing-Clinical-Development-of-FOG-001-and-Accelerate-Helicon-Peptide-Portfolio
February 29, 2024
CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference
February 27, 2024
Tyra Biosciences to Present at Upcoming Investor Conferences
February 27, 2024
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 26, 2024
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
February 20, 2024
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
February 20, 2024
Arvinas Announces Chief Financial Officer Transition
February 20, 2024
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
February 08, 2024
MOMA Therapeutics Appoints Industry Leader Jeff Albers as Chair of the Board of Directors
February 07, 2024
Tyra Biosciences to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
February 06, 2024
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
February 02, 2024
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
February 01, 2024
Revolution Medicines to Participate in Upcoming Investor Conferences
February 01, 2024
Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia
February 01, 2024
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
February 01, 2024
ITM Obtains Manufacturing License in the U.S.
January 31, 2024
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
January 30, 2024
ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program
January 30, 2024
ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program
January 26, 2024
Flare Therapeutics Presents FX-909 Phase 1 Dose Escalation and Expansion Clinical Trial Design at the 2024 ASCO Genitourinary Cancers Symposium
January 24, 2024
Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways
January 16, 2024
Arvinas Appoints Jared Freedberg as General Counsel
January 16, 2024
ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board
January 08, 2024
NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225 (Ac-225)
January 05, 2024
BioCentury’s 2022 class of emerging companies
January 04, 2024
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team
January 04, 2024
MOMA Therapeutics Announces Five-Year Discovery Collaboration with Roche Focused on Critical Cancer Dependencies
January 04, 2024
ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site
January 04, 2024
Top Life Sciences Startups to Watch in 2023
January 03, 2024
CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023
Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor
November 09, 2023
Revolution Medicines Completes Acquisition of EQRx
November 09, 2023
Revolution Medicines Completes Acquisition of EQRx
November 09, 2023
CARGO Therapeutics Announces Pricing of Initial Public Offering
November 08, 2023
Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference
November 08, 2023
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
November 08, 2023
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
November 07, 2023
Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
November 06, 2023
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
November 03, 2023
Flare Therapeutics Presents New Translational Data in Support of Lead Asset FX-909 for the Treatment of Muscle-Invasive Urothelial Cancer at SITC 2023 Annual Meeting
November 02, 2023
IDRx Presents Preliminary Clinical Data from Ongoing Phase 1 StrateGIST Study at CTOS 2023 Supporting Best-in-Class Potential of IDRX-42 in Patients with GIST
November 02, 2023
A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 01, 2023
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.
October 31, 2023
Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
October 31, 2023
Flare Therapeutics to Present New Translational Data in Support of Clinical Candidate FX-909’s Phase 1 Development at SITC 2023 Annual Meeting READ FULL STORY
October 24, 2023
Scorpion Therapeutics Appoints Precision Medicine Leader Jeff Albers as Strategic Advisor
October 24, 2023
ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics
October 22, 2023
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
October 19, 2023
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to form Sail Biomedicines
October 19, 2023
Flare Therapeutics Announces First Patients Dosed in First-in-Human Phase 1 Clinical Study of FX-909 in Advanced Solid Malignancies, Including Urothelial Cancer
October 18, 2023
ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225
October 17, 2023
CARGO Therapeutics Announces Appointment of Ginna Laport, MD, as Chief Medical Officer
October 16, 2023
A2 Bio Announces Oral and Poster Presentations at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 13, 2023
Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting
October 13, 2023
Scorpion Therapeutics Presents Preclinical Data for STX-241, a Fourth-Generation EGFR Inhibitor, at the AACR-NCI-EORTC Symposium 2023
October 13, 2023
Boundless Bio Presents Preclinical Data on the Discovery of its Second ecDNA-Directed Therapeutic Candidate, BBI-825, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 13, 2023
10.13.2023 Flare Therapeutics Presents Novel, AI-Based Method Identifying Luminal Subtype of Urothelial Cancer Supporting Lead Asset FX-909 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 10, 2023
Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer
October 09, 2023
Circle Pharma announces upcoming presentation at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 04, 2023
Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
October 04, 2023
Boundless Bio Announces Upcoming Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 02, 2023
Boundless Bio Appoints New Board Members and Establishes Clinical Advisory Board
October 01, 2023
AI Analysis of Histological Images Accurately Identifies Luminal Subtype Urothelial Carcinomas Characterized by High PPARG Expression
September 21, 2023
Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings
September 19, 2023
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
September 19, 2023
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors
September 18, 2023
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Taiho Oncology to Evaluate LYTGOBI® (futibatinib) in Combination with BBI-355 in Patients with FGFR Amplified Solid Tumors
September 12, 2023
Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference
September 12, 2023
CARGO Therapeutics Announces Appointment of Michael Ports, PhD, as Chief Scientific Officer
August 28, 2023
Fierce Biotech Names Boundless Bio a “Fierce 15” Biotech Company of 2023
August 24, 2023
CARGO Therapeutics Appoints Biotech Life Sciences Leaders to Board of Directors
August 17, 2023
Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
August 10, 2023
Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights
August 08, 2023
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
August 03, 2023
Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
August 01, 2023
Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia
August 01, 2023
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital
August 01, 2023
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital
July 31, 2023
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
July 31, 2023
Boundless Bio Appoints Jami Rubin as Chief Financial Officer
July 26, 2023
Circle Pharma strengthens its executive leadership team with two senior appointments in Clinical Development
July 19, 2023
Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B
July 17, 2023
Atavistik Bio Appoints Bryan Stuart as Chief Executive Officer
July 11, 2023
IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical Trial of its Lead Product Candidate, ICVB-1042
June 15, 2023
ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023
June 13, 2023
ITM Opens World’s Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer
June 08, 2023
Revolution Medicines to Participate in Upcoming Investor Conferences
June 05, 2023
ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities
June 01, 2023
Laronde Company Statement in Response to Inquiries from STAT News
June 01, 2023
Boundless Bio to Present at the 2023 Jefferies Healthcare Conference
May 31, 2023
IconOVir Bio to Present at Jefferies Healthcare Conference
May 31, 2023
CARGO Therapeutics to Present at the Jefferies Global Healthcare Conference
May 30, 2023
A2 Bio Announces First Patient Dosed in Phase 1 Clinical Trial of A2B530, a Novel Cell Therapy for the Treatment of Colorectal, Pancreatic and Non-small Cell Lung Cancers
May 25, 2023
Tyra Biosciences to Participate in Upcoming Investor Conferences
May 24, 2023
Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit
May 23, 2023
Exo announces lead program, targeting TANK Binding Kinase 1 (TBK1), for the treatment of autoimmune diseases
May 16, 2023
Boundless Bio Announces $100 Million Oversubscribed Series C Financing co-led by Leaps by Bayer and RA Capital Management to Advance the First ecDNA-Directed Therapies (ecDTx) for Patients with Oncogene Amplified Cancer
May 11, 2023
CULLINAN ONCOLOGY PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
May 10, 2023
PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights
May 09, 2023
Flare Therapeutics Named to Inc. Magazine’s Annual List of Best Workplaces for 2023
May 09, 2023
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification
May 08, 2023
Laronde Announces New Leadership
May 08, 2023
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
May 04, 2023
Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights
May 02, 2023
Scorpion Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of STX-478, Its Mutant-Selective PI3Kα Inhibitor for the Treatment of Breast Cancer and Other Solid Tumors
May 01, 2023
Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023
April 27, 2023
EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023
April 26, 2023
CULLINAN ONCOLOGY TO PRESENT FIRST CLINICAL DATA EVALUATING NOVEL ANTI-MICA/B ANTIBODY, CLN-619, IN PATIENTS WITH ADVANCED SOLID TUMORS AT ASCO 2023
April 19, 2023
Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting
April 17, 2023
Flare Therapeutics Presents First Preclinical Data on Lead Asset FX-909, a Novel Small Molecule PPARG Inhibitor to Potentially Treat Urothelial Cancer, at the 2023 AACR Annual Meeting
April 13, 2023
Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference
April 13, 2023
Caris Life Sciences and Flare Therapeutics Announce Strategic Preferred Portfolio Partnership to Advance Flare’s Precision Oncology Pipeline
April 06, 2023
Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023
March 30, 2023
Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions
March 29, 2023
Tyra Biosciences to Participate in Upcoming Investor Conferences
March 27, 2023
CULLINAN ONCOLOGY ANNOUNCES U.S. FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CLN-617, A NOVEL FUSION PROTEIN HARNESSING IL-2 AND IL-12 CYTOKINES
March 22, 2023
Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights
March 22, 2023
FLARE THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $123 MILLION SERIES B FINANCING
March 15, 2023
Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates
March 15, 2023
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results
March 15, 2023
Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research Annual Meeting 2023
March 14, 2023
Laronde to Present at the RNA Leaders Europe Congress
March 14, 2023
Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting
March 14, 2023
FLARE THERAPEUTICS TO PRESENT OVERVIEW OF CLINICAL CANDIDATE FX-909 AT AACR ANNUAL MEETING
March 14, 2023
CULLINAN ONCOLOGY TO PRESENT NEW PRECLINICAL DATA FOR CLN-619 AND CLN-617 AT THE 2023 AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING
March 13, 2023
Atavistik Bio Announces Publication in Science by Co-Founder Jared Rutter Describing Foundational Technology for its Atavistik Metabolite-Protein Screening (AMPS) Platform
March 12, 2023
Kinnate Biopharma Inc. Provides Statement on Silicon Valley Bank Receivership
March 09, 2023
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
March 09, 2023
CULLINAN ONCOLOGY PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
March 07, 2023
Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 07, 2023
IconOVir Bio to Present at Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023
Alpha-9 Theranostics Strengthens its Scientific Expertise with Key Appointments to Leadership Team and Scientific Advisory Board
March 01, 2023
Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia
March 01, 2023
PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights
March 01, 2023
CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies
February 28, 2023
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March
February 28, 2023
Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference
February 27, 2023
CULLINAN ONCOLOGY TO PARTICIPATE IN COWEN’S 43RD ANNUAL HEALTH CARE CONFERENCE
February 27, 2023
Arvinas to Participate in Upcoming Investor Conferences
February 23, 2023
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
February 23, 2023
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 22, 2023
Tyra Biosciences to Present at Upcoming Investor Conferences
February 21, 2023
Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People’s Republic of China
February 14, 2023
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor
February 13, 2023
Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules
February 13, 2023
CULLINAN ONCOLOGY LICENSES U.S. RIGHTS TO THE FIRST CLINICAL-STAGE B7H4 X 4-1BB BISPECIFIC IMMUNE ACTIVATOR FROM HARBOUR BIOMED
February 09, 2023
Blueprint Medicines to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
February 08, 2023
MOMA Therapeutics Appoints Industry Leader Jeff Albers as Chair of the Board of Directors
February 08, 2023
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
February 07, 2023
Theseus Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
February 07, 2023
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2023
Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference
February 06, 2023
Arvinas to Participate in Upcoming Investor Conferences
February 03, 2023
Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
February 02, 2023
FLARE THERAPEUTICS TO PRESENT AT GUGGENHEIM HEALTHCARE TALKS ONCOLOGY DAY
February 02, 2023
Revolution Medicines to Participate in Upcoming Investor Conferences
February 02, 2023
Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
February 01, 2023
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 30, 2023
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors
January 26, 2023
Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director
January 24, 2023
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
January 23, 2023
Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
January 18, 2023
A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future TmodTM CAR T Therapy
January 17, 2023
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium
January 10, 2023
Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics
January 09, 2023
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology
January 09, 2023
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
January 06, 2023
Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors
January 05, 2023
Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program
January 05, 2023
Blueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at Scale
January 04, 2023
Exo Therapeutics Appoints Nagesh Mahanthappa as Executive Chair
January 04, 2023
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2023
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 28, 2022
Boundless Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 19, 2022
EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer
December 16, 2022
Arvinas Announces Changes to its Board of Directors
December 15, 2022
Circle Pharma appoints Stephen Kelsey, MB ChB, MD, to its board of directors
December 14, 2022
Alpha-9 Theranostics Announces Oversubscribed $75 Million Series B Financing to Advance Portfolio of Radiopharmaceuticals for Cancer
December 11, 2022
Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting
December 11, 2022
Blueprint Medicines Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis
December 08, 2022
Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3Kα Inhibitor at San Antonio Breast Cancer Symposium
December 07, 2022
Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial
December 05, 2022
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
December 02, 2022
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2022
Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300
November 22, 2022
PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
November 22, 2022
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
November 17, 2022
Laronde Appoints Pablo J. Cagnoni as Chief Executive Officer
November 15, 2022
Boundless Bio to Participate at Two Upcoming Investor Conferences
November 14, 2022
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 10, 2022
Tyra Biosciences to Present at Upcoming Investor Conferences
November 10, 2022
Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates
November 10, 2022
IconOVir Announces New Preclinical Data Showcasing Best-in-Class Potential of ICVB-1042, its Lead Oncolytic Virus, at SITC 2022
November 10, 2022
EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results
November 09, 2022
Revolution Medicines to Participate in Upcoming Investor Conferences
November 09, 2022
Blueprint Medicines to Present at Upcoming Investor Conferences
November 08, 2022
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 08, 2022
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742
November 08, 2022
Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results
November 08, 2022
Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 07, 2022
Scorpion Therapeutics Announces Formation of World-Class Clinical Scientific Advisory Board
November 07, 2022
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
November 07, 2022
EQRx to Participate in the Jefferies 2022 London Healthcare Conference
November 07, 2022
A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022
November 04, 2022
PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
November 04, 2022
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2022
Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights
November 03, 2022
Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Third Quarter 2022 Financial Results
November 03, 2022
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 03, 2022
Blueprint Medicines to Present New Data Reinforcing Clinical Leadership in Systemic Mastocytosis at 2022 ASH Annual Meeting
November 02, 2022
Tyra Biosciences Announces Planned Chief Financial Officer Transition
November 02, 2022
Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors
November 01, 2022
Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
November 01, 2022
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2022
Cullinan Oncology to Participate in Upcoming Investor Conferences
November 01, 2022
Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale and Reports Third Quarter 2022 Financial Results at Investor Day 2022
November 01, 2022
Arvinas to Present at Upcoming Conferences
October 28, 2022
FLARE THERAPEUTICS PRESENTS COMPREHENSIVE REAL-WORLD DATA IN ADVANCED AND METASTATIC UROTHELIAL CANCER IN SUPPORT OF THERAPEUTIC TARGETING OF PPARG AT 2022 EORTC-NCI-AACR SYMPOSIUM
October 28, 2022
EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022
October 27, 2022
Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award
October 26, 2022
Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data for STX-721, a Next-Generation Exon 20 Mutant EGFR Inhibitor, at the EORTC-NCI-AACR Symposium 2022
October 26, 2022
FLARE THERAPEUTICS PRESENTS PRECLINICAL DATA THAT SHOW POTENTIAL OF NOVEL PPARG INHIBITORS TO TREAT UROTHELIAL CANCER AT 2022 EORTC-NCI-AACR SYMPOSIUM
October 26, 2022
Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium
October 25, 2022
Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619
October 21, 2022
https://ir.silverbacktx.com/news-releases/news-release-details/silverback-therapeutics-inc-announces-fdas-acceptance-ars
October 19, 2022
Blueprint Medicines to Host Investor Day and Announce Third Quarter 2022 Financial Results on November 1, 2022
October 19, 2022
Theseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors
October 13, 2022
Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 12, 2022
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022
October 11, 2022
Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial
October 10, 2022
IconOVir Bio Appoints Julia Maltzman, M.D., as Chief Medical Officer
October 05, 2022
IconOVir Bio to Present Preclinical Data on Lead Candidate ICVB-1042 at SITC 2022
October 03, 2022
Theseus Pharmaceuticals Nominates THE-349, a Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer
October 03, 2022
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022
Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs
September 30, 2022
Arvinas Gives Back to Local Greater New Haven Community
September 29, 2022
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
September 26, 2022
C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022
September 26, 2022
Arvinas to Present at Bank of America Securities Precision Oncology Conference
September 22, 2022
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor
September 22, 2022
Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes
September 20, 2022
Atavistik Bio Announces Formation of Scientific Advisory Board
September 15, 2022
Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies
September 14, 2022
IconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium
September 12, 2022
Scorpion Therapeutics Appoints Michael Streit, M.D. as Chief Medical Officer
September 08, 2022
Tyra Biosciences to Participate at September 2022 Investor Conferences
September 07, 2022
Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference
September 06, 2022
Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022
Theseus Pharmaceuticals to Participate at Upcoming September Investor Conferences
September 06, 2022
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 05, 2022
Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress
August 31, 2022
Arvinas to Present at Upcoming Investor Conferences
August 24, 2022
CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis
August 22, 2022
Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia
August 18, 2022
Arvinas Announces Changes to its Board of Directors
August 17, 2022
Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints
August 16, 2022
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML
August 15, 2022
Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer
August 15, 2022
Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations
August 11, 2022
EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress
August 10, 2022
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 09, 2022
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
August 09, 2022
PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
August 08, 2022
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
August 07, 2022
EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer
August 04, 2022
Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights
August 04, 2022
Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights
August 04, 2022
Laronde Appoints John Mendlein as Chief Executive Officer
August 04, 2022
Kronos Bio Reports Recent Business Progress and Second-Quarter 2022 Financial Results
August 04, 2022
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 04, 2022
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 04, 2022
Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 03, 2022
Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare Conference
August 02, 2022
Kinnate Biopharma Inc. to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 02, 2022
C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors
August 02, 2022
Blueprint Medicines Reports Second Quarter 2022 Results
August 02, 2022
IDRx Launches with $122 Million Series A Financing to Treat Cancer with Purpose-Built Precision Combination Therapies
August 01, 2022
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2022
Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference
August 01, 2022
Arvinas Appoints John Northcott as Chief Commercial Officer
July 28, 2022
Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022
July 28, 2022
EQRx to Hold Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022
July 27, 2022
Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC
July 26, 2022
Circle Pharma Appoints Paul Park, MBA, as its Chief Business Officer
July 26, 2022
Blueprint Medicines to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
July 25, 2022
Flare Therapeutics Appoints Amit Rakhit, M.D. as President and Chief Executive Officer
July 22, 2022
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 21, 2022
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
July 21, 2022
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
July 18, 2022
PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
July 14, 2022
Blueprint Medicines Publishes Inaugural Corporate Responsibility Report
July 07, 2022
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 05, 2022
Cullinan Oncology to Participate in William Blair Biotech Focus Conference
July 01, 2022
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 29, 2022
Scorpion Therapeutics Nominates STX-721 as EGFR-EXON-20 Development Candidate with a Best-in-Class Profile
June 27, 2022
Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies
June 27, 2022
IconOVir Bio Appoints William Kaelin, Jr., M.D., to Board of Directors
June 23, 2022
Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417
June 16, 2022
Team Led by Boundless Bio Scientific Founders Receives $25M Award to Better Understand Extrachromosomal DNA (ecDNA) Through Cancer Grand Challenges
June 15, 2022
Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights
June 14, 2022
EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
June 10, 2022
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress
June 09, 2022
Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis
June 09, 2022
Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference
June 08, 2022
PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference
June 07, 2022
PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation
June 06, 2022
IconOVir Bio Appoints John Huynh, Ph.D., as Chief Technology Officer
June 06, 2022
Boundless Bio to Present at the 2022 Jefferies Healthcare Conference
June 03, 2022
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 03, 2022
IconOVir Bio to Present at Jefferies Healthcare Conference
June 03, 2022
Boundless Bio Appoints Sara Weymer as Vice President, Clinical Operations
June 02, 2022
Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
June 02, 2022
Scorpion Therapeutics Announces Discovery Scientific Advisory Board
June 01, 2022
Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations
June 01, 2022
Kronos Bio Announces Participation in Upcoming Investor Conferences
June 01, 2022
Arrakis Therapeutics to Present at Jefferies Healthcare Conference
June 01, 2022
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
June 01, 2022
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2022
EQRx to Participate at Upcoming Investor Conferences
May 31, 2022
Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting
May 27, 2022
IconOVir Bio to Present at Jefferies Healthcare Conference
May 26, 2022
PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022
Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022
May 26, 2022
EQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphoma at ASCO 2022
May 26, 2022
Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting
May 20, 2022
IconOVir Bio Announces Preclinical Proof-of-Concept Data for Proprietary Mutations Designed to Improve Selectivity of Novel Oncolytic Viruses, Including Lead Product Candidate ICVB-1042
May 19, 2022
Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
May 19, 2022
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
May 18, 2022
IconOVir Bio to Present at UBS Global Healthcare Conference
May 18, 2022
Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors
May 17, 2022
Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
May 17, 2022
Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
May 17, 2022
Exo Therapeutics Appoints Stephanos Ioannidis as Executive Vice President, Drug Discovery and Catherine Scholz as Senior Vice President, Program Management
May 16, 2022
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 16, 2022
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors
May 13, 2022
EQRx Reports First Quarter 2022 Financial Results and Recent Corporate Progress
May 12, 2022
Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress
May 12, 2022
Kinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational Updates
May 12, 2022
Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl
May 12, 2022
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2022 Financial Results
May 10, 2022
PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights
May 10, 2022
MOMA Therapeutics Announces $150 Million Series B Financing
May 09, 2022
Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress
May 08, 2022
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 05, 2022
Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights
May 05, 2022
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 05, 2022
Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 04, 2022
Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results
May 03, 2022
Blueprint Medicines Reports First Quarter 2022 Results
May 03, 2022
Arvinas to Present at Bank of America Securities 2022 Healthcare Conference
May 02, 2022
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 27, 2022
PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022
EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting
April 27, 2022
Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting
April 26, 2022
Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
April 26, 2022
Exo Therapeutics Appoints Laura Kiessling to Scientific Advisory Board
April 26, 2022
Flare Therapeutics Appoints Adrian Jubb as Chief Medical Officer
April 26, 2022
Ambagon Therapeutics Appoints Gideon Bollag, Ph.D., to Scientific Advisory Board
April 21, 2022
Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022
April 18, 2022
Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248
April 15, 2022
Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting
April 15, 2022
EQRx to Hold First Quarter 2022 Financial Results Conference Call on Friday, May 13, 2022
April 11, 2022
Circle Pharma announces presentation at the American Association for Cancer Research 2022 Annual Meeting
April 08, 2022
Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer
April 08, 2022
C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader
April 08, 2022
Theseus Pharmaceuticals Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting
April 08, 2022
Boundless Bio Presents Data on the Novel Discovery of the Association Between Extrachromosomal DNA (ecDNA) and Replication Stress at the American Association for Cancer Research Annual Meeting 2022
April 06, 2022
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 05, 2022
Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences
April 05, 2022
Theseus Pharmaceuticals to Participate Virtually in Needham Healthcare Conference
April 04, 2022
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2022
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
March 31, 2022
Arrakis Therapeutics to Participate in Upcoming Investor Conferences
March 28, 2022
Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates
March 28, 2022
Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients
March 28, 2022
Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates
March 25, 2022
Blueprint Medicines’ AYVAKYT® (avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic Mastocytosis
March 23, 2022
EQRx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Progress
March 17, 2022
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 17, 2022
Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022
March 16, 2022
C4 Therapeutics Appoints Utpal Koppikar to Board of Directors
March 16, 2022
C4 Therapeutics Appoints Utpal Koppikar to Board of Directors
March 10, 2022
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
March 09, 2022
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma
March 09, 2022
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma
March 09, 2022
Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022
March 09, 2022
Cullinan Oncology to Present at the Barclays Global Healthcare Conference
March 09, 2022
EQRx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Wednesday, March 23, 2022
March 09, 2022
Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research Annual Meeting 2022
March 08, 2022
Blueprint Medicines to Showcase Broad Precision Therapy Pipeline at AACR Annual Meeting 2022
March 08, 2022
Scorpion Therapeutics to Present Mutant-Selective PI3Kα Program at AACR Annual Meeting 2022
March 08, 2022
Boundless Bio to Present at the Oppenheimer 32nd Annual Healthcare Conference
March 08, 2022
Theseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting
March 08, 2022
C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 08, 2022
Kronos Bio’s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022
March 08, 2022
Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual Meeting
March 08, 2022
Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022
March 07, 2022
Kinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies Congress
March 04, 2022
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
March 04, 2022
FierceBiotech A2 Bio’s Activator-blocker CAR-T Cell Therapies Show Early Promise in Solid Cancers
March 04, 2022
Arvinas to Present at Upcoming Investor Conferences
March 03, 2022
Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights
March 02, 2022
EQRx to Participate in Cowen’s 42nd Annual Health Care Conference
March 02, 2022
A2 Bio Publishes Key Preclinical Findings Demonstrating Potential of Its Highly Selective Tmod™ Cell Therapy Platform to Revolutionize the Treatment of Solid Tumors in Select Patients
March 01, 2022
Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference
March 01, 2022
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
March 01, 2022
Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference
February 28, 2022
Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies
February 28, 2022
Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors
February 28, 2022
Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress
February 28, 2022
Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
February 28, 2022
PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference
February 24, 2022
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
February 24, 2022
Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference
February 24, 2022
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results
February 22, 2022
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022
February 22, 2022
Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference
February 20, 2022
Boundless Bio Appoints Klaus Wagner, M.D., Ph.D., as Chief Medical Officer
February 18, 2022
A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future TmodTM CAR T Therapy
February 17, 2022
Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer
February 16, 2022
Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results
February 14, 2022
Kinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting
February 14, 2022
Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting
February 11, 2022
Blueprint Medicines to Present at Upcoming Investor Conferences
February 09, 2022
Blueprint Medicines to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 16, 2022
February 09, 2022
Theseus Pharmaceuticals to Participate Virtually in SVB Leerink Global Healthcare Conference
February 08, 2022
Arrakis Therapeutics to Present at Guggenheim Healthcare Talks Oncology Conference
February 07, 2022
Boundless Bio Appoints Amy Berkley, Ph.D., as Vice President, Program Team Leadership and Strategic Alliances
February 04, 2022
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 03, 2022
Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
February 03, 2022
PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day
February 03, 2022
Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference
February 03, 2022
Arvinas to Present at Upcoming Investor Conferences
February 02, 2022
Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development
February 02, 2022
Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
February 02, 2022
Boundless Bio to Present at the Guggenheim Oncology Conference
February 01, 2022
Ambagon: creating molecular glues for disordered proteins – BioCentury | February 1, 2022
January 28, 2022
https://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-ayvakytr-avapritinib-receives-positive-chmp
January 20, 2022
Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia
January 20, 2022
Blueprint Medicines Elevates Two Talented Leaders to its Executive Team
January 19, 2022
Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium
January 19, 2022
Alterome Therapeutics Launches With $64M Series A Financing
January 18, 2022
Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer
January 18, 2022
EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III and Stage IV Non-Small Cell Lung Cancer
January 18, 2022
Exo Therapeutics Appoints Antonio Gualberto as President of Research & Development and Chief Medical Officer
January 18, 2022
Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer
January 17, 2022
Boundless Bio Appoints Peter Krein, Ph.D., as Vice President, Precision Medicine
January 13, 2022
Scorpion Therapeutics Enters Agreement with Astrazeneca to Discover, Develop and Commercialize Novel Cancer Treatments Against Undruggable Targets
January 11, 2022
Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248
January 11, 2022
Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics
January 11, 2022
Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference
January 10, 2022
Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership
January 10, 2022
Unsprung traps keep PARP inhibitors effective
January 10, 2022
C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio
January 10, 2022
Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment
January 10, 2022
EQRx Enters Memorandum of Understanding with CVS Health to Create Cost Savings and Improve Patient Access to Innovative Medicines
January 10, 2022
Arrakis Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
January 10, 2022
Theseus Pharmaceuticals Announces First Patient Treated with THE-630 in Phase 1/2 Study in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
January 07, 2022
EQRx and Geisinger Sign Memorandum of Understanding to Provide Access to Innovative Cancer Medicines at Radically Lower Costs
January 06, 2022
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 06, 2022
PMV Pharma Announces Changes to its Board of Directors
January 06, 2022
Kinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 Milestones
January 06, 2022
Ambagon Therapeutics Launches with $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline
January 05, 2022
Blueprint Medicines Announces CEO and Leadership Transition Plan
January 05, 2022
Scorpion Therapeutics Receives Biospace Nextgen Bio “CLASS OF 2022” Recognition
January 05, 2022
Cullinan Oncology to Present at Upcoming Virtual Investor Conferences
January 05, 2022
Silverback Therapeutics to Participate in the H.C. Wainwright Bioconnect Conference
January 05, 2022
Boundless Bio Appoints Jennifer Lew to its Board of Directors
January 04, 2022
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
January 04, 2022
Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
Boundless Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
EQRx to Present at the 40th Annual J.P. Morgan Healthcare Conference
November 29, 2021
Scorpion Therapeutics Reveals Highly-Selective Lead Programs Targeting Mutant PI3Kα and EGFR EXON 20, Two Established Cancer Drivers with Broad Therapeutic Applicability
November 29, 2021
EQRx to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 24, 2021
Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742
November 24, 2021
Kronos Bio Announces Participation in Upcoming Investor Conferences
November 24, 2021
Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference
November 22, 2021
Scorpion Therapeutics Announces Appointment of Brian Piper as Chief Financial Officer
November 22, 2021
Cullinan Oncology to Participate in the Evercore ISI 4th Annual HealthconX Conference
November 22, 2021
EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa
November 22, 2021
PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference
November 19, 2021
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
November 18, 2021
EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership
November 17, 2021
Boundless Bio to Present at the Piper Sandler 33rd Annual Healthcare Conference and the Evercore ISI 4th Annual HealthCONx Conference
November 16, 2021
EQRx Launches “Remaking Medicine: On The Record” Investor Video Series
November 15, 2021
Theseus Pharmaceuticals Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results
November 12, 2021
Silverback Therapeutics Presents SBT6050-201 Trial in Progress Poster at Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
November 12, 2021
Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting 2021
November 12, 2021
PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
November 12, 2021
A2 Bio Provides First Preclinical Data Presentation for CEA and MSLN Programs, Including Trial Update at SITC 2021
November 11, 2021
Kronos Bio Appoints Roshawn Blunt to Board of Directors
November 11, 2021
Silverback Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference
November 10, 2021
C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results
November 10, 2021
Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress
November 10, 2021
Arvinas to Present at Stifel 2021 Virtual Healthcare Conference
November 10, 2021
Silverback Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 10, 2021
Kinnate Biopharma Inc. Reports Third Quarter 2021 Financial Results
November 10, 2021
Theseus Pharmaceuticals to Participate Virtually in Jefferies London Healthcare Conference
November 10, 2021
Boundless Bio to Present at the Stifel 2021 Virtual Healthcare Conference
November 10, 2021
Tyra Biosciences to Present at the 2021 Jefferies London Healthcare Conference
November 09, 2021
Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results
November 09, 2021
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 08, 2021
Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus’ Platform
November 08, 2021
Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
November 08, 2021
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
November 04, 2021
Kronos Bio Announces Participation in the BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology
November 03, 2021
Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021
November 03, 2021
Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 01, 2021
Kinnate Biopharma Inc. in Collaboration with Guardant Health Announces Initial Findings from BRAF Kinase Alteration Genomic Landscape and Real-World Clinical Outcomes Study
November 01, 2021
A2 BIO TO HIGHLIGHT PROGRAM UPDATES IN TWO PRESENTATIONS AT SITC 2021
November 01, 2021
Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GIST)
November 01, 2021
Laronde Expands Board of Directors with Leading Pharmaceutical Executives
October 28, 2021
Kinnate Biopharma Inc. Announces Transition of Chief Scientific Officer
October 25, 2021
Scorpion Therapeutics Expands Executive Leadership Team with Three Key Appointments
October 25, 2021
Flare Therapeutics Appoints Daphne Karydas as COO and CFO, and Michael Bowden, PhD, as SVP of Biology and Translation
October 19, 2021
EQRx and NHSE Sign Memorandum of Understanding to Enter into England’s First Population Health Partnership for Cancer Drugs
October 18, 2021
Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer
October 11, 2021
Turning Point Therapeutics to Present Early Clinical Data for Repotrectinib From the CARE Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress
October 08, 2021
Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference
October 08, 2021
Exo Therapeutics Appoints Dorothy Lou Bailey as Senior Vice President, Corporate Development and Strategy
October 07, 2021
Kinnate Biopharma Inc. Details Two-Part Phase 1 Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference
October 07, 2021
Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates
October 07, 2021
Boundless Bio Presents Data on Extrachromosomal DNA (ecDNA) Driven Resistance to KRASG12C Inhibitors at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021
October 06, 2021
EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs
October 06, 2021
Theseus Pharmaceuticals Announces Pricing of Initial Public Offering
October 05, 2021
Exo Therapeutics Raises $78 Million Series B Financing
October 05, 2021
MOMA Therapeutics Appoints Hans Bitter, Ph.D., as Senior Vice President and Head, Data Science
October 05, 2021
Silverback Therapeutics to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Conference
October 04, 2021
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors PDF Version
September 30, 2021
Kinnate Biopharma Inc. to Present Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference
September 30, 2021
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021
September 30, 2021
Turning Point Therapeutics Announces Additional Details for Three Data Presentations at the 2021 AACR-NCI-EORTC Conference
September 30, 2021
Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
September 27, 2021
Fierce Biotech’s 2021 Fierce 15
September 27, 2021
Fierce Biotech names MOMA Therapeutics as one of its “Fierce 15” Biotech Companies of 2021
September 27, 2021
EQRx Appoints Kathy Giusti to Board of Directors
September 23, 2021
Boundless Bio to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
September 22, 2021
Scorpion Therapeutics Named to the 2021 ENDPOINTS 11
September 22, 2021
Vividion Therapeutics Announces Formation of Scientific Advisory Board
September 22, 2021
Boundless Bio Announces Upcoming Presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021
September 22, 2021
Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes
September 17, 2021
EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021
September 15, 2021
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
September 14, 2021
Kronos Bio Appoints Marni Kottle as Senior Vice President of Corporate Communications and Investor Relations
September 13, 2021
Silverback Therapeutics to Present Data from its Phase 1/1b Clinical Trial of SBT6050 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress
September 13, 2021
EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC
September 13, 2021
Kinnate Biopharma Inc. Presents Preclinical Data on its Lead FGFR Inhibitor Candidate at the JCA-AACR Precision Cancer Medicine International Conference
September 09, 2021
Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors
September 09, 2021
PMV Pharmaceuticals Appoints Tim Smith as Senior Vice President, Head of Corporate Development
September 08, 2021
MOMA Therapeutics Appoints Semi Trotto as Chief People and Experience Officer
September 08, 2021
Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference
September 08, 2021
Laronde Attracts $440M in First External Financing to Further Advance Endless RNA™ Platform
September 07, 2021
Silverback Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021
EQRx to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
September 07, 2021
Kronos Bio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021
Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 01, 2021
Turning Point Therapeutics to Participate In Upcoming Investor Conferences
September 01, 2021
Arvinas to Participate in Upcoming Virtual Investor Conferences
August 30, 2021
Boundless Bio Appoints Jessica Oien as General Counsel and Corporate Secretary
August 24, 2021
Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer
August 18, 2021
EQRx Appoints Richard Buckley as Chief Corporate Affairs Officer
August 16, 2021
Kinnate Biopharma Inc. Reports Second Quarter 2021 Financial Results
August 16, 2021
Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors
August 13, 2021
PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights
August 12, 2021
Silverback Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 12, 2021
Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results
August 11, 2021
C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
August 11, 2021
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma
August 11, 2021
Turning Point Therapeutics Granted Sixth Regulatory Designation for Repotrectinib
August 11, 2021
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress
August 10, 2021
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 09, 2021
Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates
August 09, 2021
Boundless Bio Appoints Neil Abdollahian as Chief Business Officer
August 06, 2021
EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III
August 05, 2021
Cullinan Oncology to Participate in the 41st Annual Canaccord Genuity Growth Conference
August 05, 2021
Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 05, 2021
Bayer Strengthens Drug Discovery Platform Through Acquisition of Vividion Therapeutics
August 04, 2021
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
August 04, 2021
Black Diamond Therapeutics to Present at Upcoming Investor Conferences
August 04, 2021
Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021
August 03, 2021
Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
July 28, 2021
Press Releases Turning Point Therapeutics to Host Second Quarter 2021 Conference Call
July 27, 2021
Kinnate Biopharma Inc. to Participate in the 2021 Wedbush PacGrow Healthcare Conference
July 27, 2021
Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)
July 22, 2021
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
July 20, 2021
EQRx Announces Formation of Mission Advisory Board
July 12, 2021
Circle Pharma appoints Evelyn Wang, PhD as its Vice President, Translational Medicine
July 07, 2021
Scorpion Therapeutics Announces New CEO Axel Hoos, M.D., Ph.D.
July 07, 2021
Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo® (cemiplimab), initially in HER2-expressing Non-Small Cell Lung and Gastric Cancers
July 07, 2021
Kinnate Biopharma Inc. to Participate in the William Blair Biotech Focus Conference 2021
July 01, 2021
EQRx Appoints Carlos Garcia-Echeverria, Ph.D., as Chief of Rx Creation
June 29, 2021
Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors
June 29, 2021
Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer
June 28, 2021
Kinnate Biopharma Inc. Appoints Helen Sabzevari, Ph.D. to Board of Directors
June 24, 2021
EQRx and Exscientia Enter Strategic Drug Creation, Development, and Commercialization Collaboration to Accelerate the Advancement of New World-Class Medicines
June 24, 2021
Vividion Therapeutics Earns First Milestone Payment for Advancement of Program Addressing High Value Oncology Target
June 24, 2021
Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1
June 21, 2021
C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma
June 17, 2021
Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer
June 16, 2021
C4 Therapeutics Announces Pricing of Public Offering
June 16, 2021
Circle Pharma raises $66 Million in Series C Financing
June 15, 2021
Silverback Therapeutics to Participate in the Raymond James Human Health Innovation Conference
June 14, 2021
C4 Therapeutics Launches Proposed Public Offering
June 14, 2021
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies
June 10, 2021
Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors
June 10, 2021
Theseus Pharmaceuticals Appoints Kathy Yi to Board of Directors and Chair of Audit Committee
June 09, 2021
PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference
June 07, 2021
C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation
June 07, 2021
Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML
June 07, 2021
Kinnate Biopharma Inc. Appoints Neha Krishnamohan as CFO and Executive Vice President, Corporate Development and Expands its Leadership Team with Key New Hires
June 07, 2021
Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven
June 04, 2021
Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients
June 04, 2021
Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021
June 03, 2021
PMV Pharmaceuticals Announces Participation at the Goldman Sachs Annual Healthcare Conference
June 03, 2021
Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference
June 02, 2021
Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
June 02, 2021
Theseus Pharmaceuticals Appoints Brad Dahms as Chief Financial Officer
June 01, 2021
Silverback Therapeutics to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
June 01, 2021
Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference
May 28, 2021
Primary Endpoint Met in Phase 3 Study of the Anti-PD-L1 Antibody Sugemalimab in Stage III Non-Small Cell Lung Cancer
May 27, 2021
IconOVir Bio to Present at Jefferies Healthcare Conference
May 26, 2021
C4 Therapeutics to Advance CFT8919, a Selective Degrader of EGFR L858R, into IND-Enabling Studies
May 26, 2021
Kronos Bio Announces Participation in Upcoming Investor Conferences
May 25, 2021
Kinnate Biopharma Inc. to Participate at the Goldman Sachs 42nd Annual Global Healthcare Conference
May 25, 2021
Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today
May 25, 2021
Turning Point Therapeutics Names Former Celgene Chairman and CEO, Mark Alles, to Chair Its Board of Directors
May 21, 2021
Cullinan Oncology Announces Management Transition
May 20, 2021
C4 Therapeutics Appoints Lauren White as Chief Financial Officer
May 20, 2021
IconOVir Bio Announces Preclinical Proof-of-Concept Data for Proprietary Mutations Designed to Improve Selectivity of Novel Oncolytic Viruses, Including Lead Product Candidate ICVB-1042
May 20, 2021
Arvinas to Present at the UBS Global Healthcare Virtual Conference
May 19, 2021
Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021
May 19, 2021
Aumolertinib Significantly Prolongs Progression Free Survival with Fewer Side Effects in the First-Line Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
May 19, 2021
Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations
May 18, 2021
Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit
May 17, 2021
Kinnate Biopharma Inc. Reports First Quarter 2021 Financial Results and Announces FDA Clearance of Investigational New Drug Application for KIN-2787
May 17, 2021
Black Diamond Therapeutics to Host Webcast Presentation of Data From Phase 1 Dose-Escalation Portion of MasterKey-01 Clinical Trial
May 17, 2021
Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer
May 17, 2021
Boundless Bio Announces Educational Session on Extrachromosomal DNA (ecDNA) at the American Association for Cancer Research (AACR) Annual Meeting 2021
May 14, 2021
Cullinan Oncology Reports First Quarter 2021 Financial Results
May 14, 2021
PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights
May 13, 2021
C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
May 13, 2021
Silverback Therapeutics Reports First Quarter 2021 Financial Results
May 13, 2021
Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture
May 13, 2021
Flare Therapeutics Launches With $82 Million Series A Financing to Advance Precision Oncology Pipeline Based on Novel Drug Discovery Approach for Transcription Factors
May 12, 2021
C4 Therapeutics to Present at Upcoming Investor Conferences
May 11, 2021
Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day
May 10, 2021
Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO
May 10, 2021
Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress
May 07, 2021
Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021
Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference
May 05, 2021
PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference
May 05, 2021
Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Operational Updates
May 04, 2021
Vividion Therapeutics Appoints Christine Siu to Board of Directors
May 04, 2021
Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven
May 04, 2021
Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 04, 2021
Theseus Pharmaceuticals Appoints Tim Clackson, Ph.D., as Chief Executive Officer
May 03, 2021
MOMA Therapeutics Appoints Peter Hammerman, M.D., Ph.D., as Chief Scientific Officer
May 03, 2021
Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting
April 30, 2021
Kinnate Biopharma Inc. Announces the Departure of Dr. Stephen Kaldor from its Board of Directors
April 28, 2021
Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA)
April 28, 2021
Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology
April 26, 2021
Turning Point Therapeutics to Host First Quarter 2021 Conference Call
April 21, 2021
Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors
April 20, 2021
IconOVir Bio Announces Formation of Scientific Advisory Board
April 20, 2021
Vividion Therapeutics Expands Leadership Team with Key Regulatory and CMC Appointments
April 19, 2021
EQRx Appoints Jami Rubin as Chief Financial Officer and Kent Rogers as Chief Customer Officer
April 13, 2021
Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
April 12, 2021
Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor
April 10, 2021
Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021
April 10, 2021
Black Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting
April 09, 2021
Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates
April 08, 2021
Silverback Therapeutics to Present SBT6290 Preclinical Data at the AACR 2021 Annual Conference
April 07, 2021
Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference
April 06, 2021
PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum
April 05, 2021
Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
April 05, 2021
Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046
March 31, 2021
Tyra Biosciences raises $106M in Series B financing to advance novel pipeline of therapies targeting acquired resistance in oncology
March 31, 2021
Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D.
March 31, 2021
Turning Point Therapeutics Announces Board Changes
March 30, 2021
Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights
March 30, 2021
Vividion Names Patty Allen as Full-Time Chief Financial Officer and Welcomes Brian Koh, M.D., as Head of Translational Sciences and Clinical Development
March 30, 2021
Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021
March 29, 2021
Silverback Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Updates
March 29, 2021
Kinnate Biopharma Inc. Reports Full Year 2020 Financial Results
March 28, 2021
Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology
March 26, 2021
Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors
March 25, 2021
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 24, 2021
Vividion Appoints Catherine Friedman to Board of Directors
March 23, 2021
Arrakis Therapeutics Announces New Scientific Advisory Board Members
March 23, 2021
Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
March 19, 2021
Kinnate Biopharma Inc. Announces Its Addition to the Russell 2000® Index
March 15, 2021
Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors
March 11, 2021
C4 THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FULL YEAR 2020 FINANCIAL RESULTS
March 11, 2021
Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
March 10, 2021
C4 THERAPEUTICS TO PRESENT ON THE DISCOVERY AND PRECLINICAL DEVELOPMENT OF CFT7455, A MONODAC™ DEGRADER TARGETING IKZF1/3, AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING
March 10, 2021
PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
March 10, 2021
Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
March 10, 2021
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting
March 10, 2021
Turning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at American Association For Cancer Research Annual Meeting
March 10, 2021
Arvinas to Participate in Upcoming Virtual Investor Conferences
March 09, 2021
Revolution Medicines to Participate in Upcoming Investor Conferences
March 04, 2021
Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)
March 04, 2021
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
March 03, 2021
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
March 02, 2021
Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference
March 02, 2021
Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021
March 02, 2021
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress
March 01, 2021
Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 01, 2021
Turning Point Therapeutics Reports Fourth-Quarter and Full-Year Financial Results, Provides Operational Updates
February 25, 2021
Scorpion Therapeutics Announces Leadership Change
February 24, 2021
Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs
February 23, 2021
PMV Pharmaceuticals Announces Participation at the Cowen 41st Annual Health Care Conference
February 23, 2021
Black Diamond Therapeutics to Present at Upcoming Investor Conferences
February 22, 2021
Cullinan Management, Inc. Announces Business Update
February 22, 2021
Aumolertinib Phase 3 Study Meets Primary Endpoint in First-Line Treatment for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
February 22, 2021
Kronos Bio Announces Participation in the Cowen 41st Annual Health Care Conference
February 18, 2021
Turning Point Therapeutics to Host Fourth Quarter and Full-Year 2020 Conference Call
February 18, 2021
Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences
February 16, 2021
Silverback Therapeutics to Present at Upcoming Investor Conferences
February 16, 2021
PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board
February 11, 2021
C4 Therapeutics to Participate in BMO Biopharma Spotlight Series
February 11, 2021
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
February 11, 2021
Black Diamond Therapeutics to Present at the BMO Biopharma Spotlight Series
February 08, 2021
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 08, 2021
Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day
February 04, 2021
Turning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
February 03, 2021
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock
February 01, 2021
Circle Pharma appoints Constantine Kreatsoulas, PhD as its Vice President, Research Informatics and Computational Chemistry
February 01, 2021
MOMA Therapeutics Appoints Asit Parikh, M.D., Ph.D. as President and Chief Executive Officer
February 01, 2021
Revolution Medicines Announces Proposed Public Offering of Common Stock
January 29, 2021
Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer
January 27, 2021
Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors
January 20, 2021
Black Diamond Therapeutics Announces Appointment of Oncology Clinical Development Veteran Dr. Kapil Dhingra to Board of Directors
January 19, 2021
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic Malignancies
January 12, 2021
Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 11, 2021
EQRx Scales Disruptive Model of Important New Medicines at Lower Prices with $500M Series B Financing
January 10, 2021
Tyra Biosciences raises $50M to develop therapies targeting acquired resistance in oncology
January 07, 2021
Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing
January 07, 2021
C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 07, 2021
Vividion Appoints Patty Allen, Experienced Financial Executive, as Acting Chief Financial Officer
January 07, 2021
Cullinan Management Announces Pricing of Upsized Initial Public Offering
January 06, 2021
C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022
January 05, 2021
Black Diamond Therapeutics to Present at the J.P. Morgan 39th Annual Healthcare Conference
January 05, 2021
Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference
December 28, 2020
Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares
December 23, 2020
A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers
December 17, 2020
C4 Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
December 15, 2020
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
December 14, 2020
Arvinas, Inc. Announces Proposed Offering of Common Stock
December 14, 2020
Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110
December 11, 2020
Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC® Protein Degrader Development Programs
December 08, 2020
Kronos Bio Appoints Pasit Phiasivongsa, Ph.D., as Senior Vice President, Pharmaceutical Development
December 08, 2020
Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 07, 2020
Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
December 07, 2020
Kronos Bio Announces FDA Clearance of Investigational New Drug (IND) Application for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
December 03, 2020
Silverback Therapeutics Announces Pricing of Initial Public Offering
December 02, 2020
Kinnate Biopharma Announces Pricing of Initial Public Offering
November 25, 2020
Arvinas to Participate in Upcoming Virtual Investor Conferences
November 25, 2020
C4 Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx
November 24, 2020
Black Diamond Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24, 2020
PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference
November 23, 2020
Vividion Brings in Proven Industry Leader Jeffrey Hatfield as Chief Executive Officer
November 23, 2020
Kronos Bio Announces Participation in Upcoming Investor Conferences
November 23, 2020
PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53
November 20, 2020
Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting
November 19, 2020
Arrakis Therapeutics Appoints Patrizio Renzetti as Vice President of Human Resources
November 18, 2020
Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results
November 13, 2020
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
November 13, 2020
Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting Digital Experience
November 13, 2020
C4 Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
November 12, 2020
C4 Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results
November 12, 2020
Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress
November 11, 2020
Black Diamond Therapeutics to Present at the Jefferies 2020 Virtual London Healthcare Conference
November 11, 2020
Kronos Bio Announces Participation in the Jefferies Virtual London Healthcare Conference
November 10, 2020
Black Diamond Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 10, 2020
Silverback Therapeutics Expands Executive Team With Appointment of Healthcare Investment Banking Veteran Jonathan Piazza as Chief Financial Officer
November 09, 2020
Silverback Therapeutics to Present Data on Two Programs at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting
November 05, 2020
Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update
October 26, 2020
Scorpion Therapeutics Launches with $108 Million to Advance Precision Oncology 2.0
October 26, 2020
Circle Pharma Appoints James Aggen, PhD as Its Vice President, Medicinal Chemistry
October 26, 2020
Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium
October 24, 2020
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
October 22, 2020
Kronos Bio Announces Publication of Preclinical Study Results for Investigational CDK9 Inhibitor KB-0742 in Cell Chemical Biology
October 21, 2020
Circle Pharma Appoints Alan Ashworth, PhD, FRS and Bruce Stillman, PhD, FRS to Its SAB
October 14, 2020
Kronos Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 14, 2020
Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins
October 14, 2020
C4 Therapeutics to Present at the 3rd Annual Targeted Protein Degradation Summit
October 13, 2020
PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation
October 12, 2020
Black Diamond Therapeutics to Present Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium
October 12, 2020
Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors
October 08, 2020
Kronos Bio Announces Pricing of Initial Public Offering
October 06, 2020
C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
October 06, 2020
Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit
October 01, 2020
C4 Therapeutics Announces Pricing of an Upsized Initial Public Offering
September 29, 2020
PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
September 29, 2020
Black Diamond Therapeutics Announces the Appointment of Biopharmaceutical Veteran Robert A. Ingram as Chairman of the Board
September 24, 2020
PMV Pharma Announces Pricing of Initial Public Offering
September 23, 2020
Silverback Therapeutics™ Raises $85 Million in Series C Financing; Company Announces Executive Promotions
September 16, 2020
Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors
September 15, 2020
Kronos Bio Appoints Elena Ridloff, CFA, to Board of Directors
September 14, 2020
EQRx Strengthens Team with Industry Leaders in Drug Development, Patient Access and Organizational Culture
September 10, 2020
Black Diamond Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference
September 09, 2020
Revolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 09, 2020
Kinnate Biopharma Appoints Dean J. Mitchell as Chairman of the Board
September 08, 2020
Black Diamond Therapeutics Announces the Appointment of Rachel Humphrey, M.D., as Chief Medical Officer
September 08, 2020
PMV Pharma Appoints Laurie Stelzer to the Board of Directors and Robert Ticktin as General Counsel
September 08, 2020
Andrew Hirsch Named Chief Executive Officer of C4 Therapeutics
September 08, 2020
Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference
September 04, 2020
Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference
August 31, 2020
Arrakis Therapeutics Publishes Advanced Research Method To Systematically Identify RNA-Targeted Small Molecules
August 26, 2020
https://arrakistx.com/news/press-releases/arrakis-therapeutics-publishes-advanced-research-method-to-systematically-identify-rna-targeted-small-molecules/
August 26, 2020
Silverback Therapeutics™ Initiates Phase 1 Clinical Study of SBT6050
August 26, 2020
Kinnate Biopharma Closes $98 Million Series C Financing
August 24, 2020
Kronos Bio Announces $155 Million Private Financing
August 19, 2020
Kronos Bio Appoints Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development
August 11, 2020
Black Diamond Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 10, 2020
Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress
August 07, 2020
Arvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference
August 05, 2020
Black Diamond Therapeutics to Present at Upcoming Investor Conferences
August 04, 2020
Black Diamond Therapeutics Announces the Appointment of Fang Ni as Chief Business Officer
August 04, 2020
Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 03, 2020
PMV Pharma Closes $70 Million in Series D Financing
August 03, 2020
Dr. Rich Heyman appointed as Chair of the Board of Directors of PMV Pharma
July 28, 2020
Black Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of Adult Patients with a Solid Tumor Harboring an Allosteric HER2 Mutation or an EGFR or HER2 Exon 20 Insertion Mutation
July 20, 2020
Circle Pharma Appoints Rajinder Singh, PhD as its Chief Science Officer
July 20, 2020
Kronos Bio Appoints Barbara Kosacz, Chief Operating Officer and General Counsel
July 16, 2020
Kronos Bio and Gilead Sciences Enter Into Asset Purchase Agreement for Gilead’s SYK Inhibitor Portfolio
July 15, 2020
Arrakis Therapeutics Appoints Erik Spek, Ph.D., J.D., as Vice President, Legal and Intellectual Property
July 15, 2020
C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer
July 13, 2020
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 09, 2020
Kronos Bio Reports Positive Results of Preclinical Study of KB-0742, an Investigational CDK9 Inhibitor, Demonstrating Potency, Selectivity and Anti-tumor Activity in Prostate Cancer Model
July 08, 2020
Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock
July 08, 2020
Kinnate Biopharma Appoints Dr. Richard Williams as Chief Medical Officer
July 07, 2020
Kronos Bio Appoints Industry Veteran, Jennifer Nicholson, M.H.A., as Vice President, Regulatory Affairs
July 06, 2020
Revolution Medicines Announces Proposed Public Offering of Common Stock
June 30, 2020
Revolution Medicines Reports New Application of Tri-Complex Modality for “Undruggable” Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel Coronavirus
June 29, 2020
Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors
June 22, 2020
Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor
June 22, 2020
Revolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer Therapies
June 22, 2020
Silverback Therapeutics™ to Present Preclinical Data on SBT6050 Demonstrating Potent Activation of Human Myeloid Cells and the Potential for Single Agent Clinical Activity
June 18, 2020
Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors
June 17, 2020
Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference
June 16, 2020
Precision Oncology News: Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next Year
June 16, 2020
C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-concept and to Advance Proprietary Platform
June 16, 2020
Black Diamond Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
June 16, 2020
Kronos Bio Expands Leadership Team with Appointment of Seasoned Drug Discovery Leader Christopher Dinsmore, Ph.D., as Chief Scientific Officer
June 11, 2020
Arvinas Appoints Linda Bain to its Board of Directors
June 09, 2020
Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510
June 08, 2020
IDEAYA Announces Nomination of Development Candidate, IDE397, for MAT2A Synthetic Lethality Program Targeting MTAP-Deletion Patient Population
June 05, 2020
Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference
June 04, 2020
Silverback Therapeutics™ Appoints Vickie L. Capps to Board of Directors and Audit Committee Chair
May 29, 2020
Silverback Therapeutics™ Announces Presentation of Preclinical Data at ASCO Supporting Potential Clinical Activity of SBT6050 as a Single Agent and in Combination with Trastuzumab for the Treatment of HER2-Expressing Malignancies
May 29, 2020
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer
May 27, 2020
Kinnate Biopharma Appoints Nima Farzan as Chief Executive Officer
May 27, 2020
Circle Pharma Appoints William G. Kaelin Jr. MD as Chair of Its Scientific Advisory Board
May 27, 2020
Black Diamond Therapeutics to Present at the Jefferies Virtual Healthcare Conference
May 26, 2020
Kronos Bio Announces Participation in the Jefferies Virtual Healthcare Conference
May 20, 2020
Arvinas to Hold Virtual 2020 Annual Meeting of Stockholders
May 19, 2020
IDEAYA Biosciences to Participate in Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020
May 19, 2020
Vividion Announces $135M Up-Front Drug Discovery Collaboration with Roche
May 19, 2020
Kronos Bio Expands Clinical Team with the Appointment of Zung To as Vice President, Clinical Operations
May 19, 2020
Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II
May 15, 2020
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ/11 Tumors and Preclinical MAT2A Synthetic Lethality Program
May 15, 2020
Silverback Therapeutics™ to Present Preclinical Data from Lead ImmunoTAC™ Candidate, SBT6050, at Upcoming ASCO Virtual Scientific Program and AACR Virtual Annual Meeting
May 14, 2020
Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress
May 13, 2020
Black Diamond Therapeutics Announces Accepted Abstract for Lead Product Candidate BDTX-189 at American Society of Clinical Oncology 2020
May 13, 2020
Arvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC® Protein Degrader ARV-110 in Patients with Refractory Prostate Cancer
May 12, 2020
IDEAYA Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
May 12, 2020
Black Diamond Therapeutics Reports First Quarter 2020 Financial Results and Corporate Update
May 06, 2020
Black Diamond Therapeutics to Present at the Bank of America Global Research Health Care Conference 2020
April 29, 2020
Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
April 28, 2020
Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update
April 22, 2020
Silverback Therapeutics™ Announces Appointment of Veteran Executive Laura Shawver, Ph.D. as President and CEO
April 21, 2020
IDEAYA Biosciences Announces Addition of Julie Patel as Vice President, Human Resources, Enhancing its Leadership Team
April 15, 2020
MOMA Therapeutics: Drugging the molecular machines that underlie human disease
April 13, 2020
Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 Pandemic
April 08, 2020
Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform
March 31, 2020
Arvinas to Present at the American Society of Clinical Oncology Annual Meeting
March 24, 2020
IDEAYA Biosciences, Inc. Reports Fourth Quarter 2019 Financial Results and Provides Business Update
March 24, 2020
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
March 18, 2020
IDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update
March 18, 2020
Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program
March 18, 2020
IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations
March 17, 2020
Circle Pharma raises $45 Million in Series B Financing
March 16, 2020
Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 11, 2020
Silverback Therapeutics Raises $78.5 Million in Oversubscribed Series B Financing
March 11, 2020
IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities
March 09, 2020
New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute
March 09, 2020
Blueprint Medicines to Report Updated Data from the Phase 2 PIONEER Trial of Avapritinib in Indolent Systemic Mastocytosis on Monday, March 16, 2020
March 09, 2020
New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute
February 24, 2020
Black Diamond Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
February 18, 2020
Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 13, 2020
Blueprint Medicines Reports Fourth Quarter and Full Year 2019 Financial Results
February 12, 2020
Revolution Medicines Announces Pricing of Initial Public Offering
February 06, 2020
Blueprint Medicines Announces PDUFA Date Extension for New Drug Application of Avapritinib for the Treatment of Adults with Fourth-Line Gastrointestinal Stromal Tumor
February 05, 2020
Arrakis Therapeutics Appoints Jacques Dumas, Ph.D., as Senior Vice President, Drug Discovery
February 03, 2020
Black Diamond Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
January 16, 2020
BioNTech to acquire Neon to strengthen global leadership position in T cell therapies
January 15, 2020
IDEAYA Biosciences Announces Synthetic Lethality Research Highlights and Target Milestones for 2020
January 13, 2020
Revolution Medicines Presents Data from its SHP2 and Oncogenic RAS(ON) Programs at 6th AACR-IASLC International Joint Conference
January 12, 2020
Bolstered with $200M Series A Financing, EQRx Brings Blue-Chip Investors and Life Sciences Leaders Together to Re-Make the Business of Drug Discovery, Development and Delivery to Patients
January 10, 2020
IDEAYA Biosciences and Boston Children’s Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome – a Rare Disease Associated with Genetic Mutation of GNAQ
January 10, 2020
Kronos Bio To Present At The 38th Annual J.P. Morgan Healthcare Conference
January 09, 2020
Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
January 09, 2020
Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
January 07, 2020
Revolution Medicines to Present Preliminary Data from Phase 1 Clinical Trial of RMC-4630 at 6th AACR-IASLC International Joint Conference
January 06, 2020
Turning Point Therapeutics Names Homa Yeganegi Senior Vice President, Project Team Leader and Head of Medical Affairs
January 06, 2020
CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma
January 06, 2020
IDEAYA Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020
January 06, 2020
Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer
December 19, 2019
Kinnate Biopharma Closes $74.5M Series B Financing
December 18, 2019
IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors
December 18, 2019
Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01
December 17, 2019
Turning Point Therapeutics to Participate in 38th Annual J.P. Morgan Healthcare Conference
December 16, 2019
Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial
December 11, 2019
PMV Pharma Appoints Leila Alland, M.D., as Chief Medical Officer
December 09, 2019
IDE196 Program Updates: Targeting Initiation of Potentially Registration-Enabling Phase 2 Single-Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020
December 08, 2019
Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis Showing Activity at All Dose Levels Tested
December 08, 2019
Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
December 05, 2019
Black Diamond Therapeutics Closes $85 Million Series C Financing
November 27, 2019
Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference
November 21, 2019
Arrakis Therapeutics Appoints Katrine Bosley as Chairman of the Board of Directors
November 21, 2019
Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors
November 20, 2019
Kronos Bio Appoints Biopharma Industry Veteran Jorge F. DiMartino, M.D., Ph.D., as Chief Medical Officer
November 20, 2019
Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress
November 20, 2019
Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs
November 19, 2019
Arrakis Therapeutics Appoints Elizabeth Radcliffe as Vice President of Finance and Strategy
November 13, 2019
PMV Pharma Secures $62 Million in Series C Financing To Develop Cancer Drugs Targeting p53
November 13, 2019
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
November 13, 2019
IDEAYA Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update
November 12, 2019
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients
November 12, 2019
Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights
November 11, 2019
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor
November 06, 2019
Arvinas, Inc. Announces Proposed Offering of Common Stock
November 06, 2019
Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition
November 06, 2019
Arvinas, Inc. Announces Pricing of Public Offering of Common Stock
November 05, 2019
A2 BIOTHERAPEUTICS EMERGES FROM STEALTH MODE WITH $57M SERIES A TO DEVELOP A PIPELINE OF SELECTIVE TUMOR CELL THERAPEUTICS
November 05, 2019
Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results
November 05, 2019
Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 05, 2019
IDEAYA Biosciences Announces Leadership Updates in Research Organization
November 04, 2019
Revolution Medicines and Amgen Partner on Phase 1b Study to Evaluate Combination of RMC-4630 and AMG 510
November 04, 2019
Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 04, 2019
Kura Oncology Appoints James Basta as Chief Legal Officer
October 31, 2019
IDEAYA Biosciences Reports End‑of‑Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma
October 30, 2019
Kura Oncology to Report Third Quarter 2019 Financial Results
October 29, 2019
Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
October 28, 2019
Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
October 24, 2019
Kronos Bio Strengthens Senior Management Team with New Leadership Appointments
October 22, 2019
Revolution Medicines to Present Preclinical Data on Novel Inhibitors of Oncogenic RAS(ON) Mutants at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 16, 2019
Ipsen and Blueprint Medicines announce exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP)
October 15, 2019
Kura Oncology Expands Board of Directors with Appointment of Diane Parks
October 09, 2019
William Kaelin named Nobel Prize winner
October 08, 2019
IDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors outside of Uveal Melanoma and a Collaboration with Foundation Medicine in support of its Tumor-Agnostic GNAQ/11 Basket Trial
October 02, 2019
Arvinas Strengthens Scientific Advisory Board with Leaders in Oncology and Neurological Disorders
October 01, 2019
Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio
September 30, 2019
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor
September 26, 2019
Black Diamond Therapeutics to Present Preclinical Data on its Lead Product Candidate BDTX-189 at the European Society for Medical Oncology 2019
September 19, 2019
Black Diamond Therapeutics Names Christopher Roberts, Ph.D.,
as Chief Scientific Officer
September 17, 2019
Revolution Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor
September 16, 2019
Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia
September 12, 2019
Black Diamond Therapeutics Appoints Thomas Leggett as Chief Financial Officer
September 05, 2019
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens
September 03, 2019
Turning Point Therapeutics Announces Proposed Public Offering of Common Stock
September 03, 2019
Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib and Preclinical Data for TPX-0046, a Novel RET/SRC Inhibitor
September 03, 2019
Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma
August 27, 2019
Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC® Protein Degrader
August 12, 2019
IDEAYA Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
August 12, 2019
Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer
August 07, 2019
Kronos Bio Expands Scientific Advisory Board with Addition of Roger D. Kornberg, Ph.D.
August 07, 2019
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
August 06, 2019
Neon Therapeutics Reports Second Quarter 2019 Financial Results
August 01, 2019
Blueprint Medicines Reports Second Quarter 2019 Financial Results
August 01, 2019
Kura Oncology Reports Second Quarter 2019 Financial Results and Provides Corporate Update
July 31, 2019
Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors
July 29, 2019
Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer
July 27, 2019
Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk
July 24, 2019
Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia
July 18, 2019
Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFRα D842V Mutant GIST and Fourth-Line GIST
July 15, 2019
Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers
July 11, 2019
IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1/2 Tissue-Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations
July 09, 2019
IDEAYA Biosciences Strengthens Management with Internal Appointments of Paul Stone, J.D., as Chief Financial Officer, Andres Ruiz Briseno, C.P.A., as Vice President, Finance, and Mick O’Quigley, M.B.A, as Vice President, Development Operations
June 25, 2019
Arvinas Receives Authorization to Proceed for ARV-471, a PROTAC® Protein Degrader to Treat Patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer
June 19, 2019
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock
June 15, 2019
Blueprint Medicines Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA Congress
June 14, 2019
Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
June 14, 2019
Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma
June 04, 2019
Bayer and Arvinas to Collaborate on Human PROTAC® Therapies and Launch a Separate Joint Venture to Develop Agricultural PROTAC® Applications
June 03, 2019
Blueprint Medicines’ Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019
May 29, 2019
ARVINAS RECEIVES FAST TRACK DESIGNATION FOR ITS TARGETED PROTEIN DEGRADER ARV-110 AS A TREATMENT FOR MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
May 22, 2019
IDEAYA Announces Pricing of Initial Public Offering
May 21, 2019
Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline
May 16, 2019
Blueprint Medicines Announces Data Presentations at ASCO and EHA Meetings from Registration-Enabling Clinical Trials of Avapritinib and BLU-667 Across Multiple Patient Populations
May 08, 2019
IDEAYA Receives Authorization to Proceed with Phase 1/2 Tissue-Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ/11 Mutations and PKC Fusions
April 30, 2019
Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing
April 22, 2019
Turning Point Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 18, 2019
Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA
April 08, 2019
Neon Therapeutics Announces Completion of Enrollment in Phase 1b NT-002 Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer
April 02, 2019
ARVINAS STRENGTHENS MANAGEMENT TEAM WITH INTERNAL APPOINTMENTS OF ANDY CREW, PH.D. AS CHIEF TECHNOLOGY OFFICER AND IAN TAYLOR, PH.D. AS CHIEF SCIENTIFIC OFFICER
April 02, 2019
Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications
April 01, 2019
Turning Point Therapeutics’ Kinase Inhibitors Show High Potency Against Targeted Oncogene Drivers And Their Mutations
March 31, 2019
Neon Therapeutics Presents Updated Data from Ongoing Phase 1b NT-001 Clinical Trial of Personal Neoantigen Vaccine NEO-PV-01 at AACR 2019 Annual Meeting
March 25, 2019
Turning Point Therapeutics Appoints Jim Mazzola To Lead Corporate Communication And Investor Relations
March 20, 2019
Protein-slaying drugs could be the next blockbuster therapies
March 06, 2019
First targeted protein degrader hits the clinic
March 05, 2019
Kura Oncology Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539
February 13, 2019
IDEAYA Biosciences appoints Leading Cancer Researchers Frank McCormick, Ph.D., FRS, and William Sellers, M.D., to Scientific Advisory Board
January 18, 2019
Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression
January 04, 2019
ARVINAS RECEIVES AUTHORIZATION TO PROCEED FOR ITS IND APPLICATION FOR PROTAC™ THERAPY TO TREAT PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
January 04, 2019
Blueprint Medicines Announces “2020 Blueprint” Global Business Strategy and Outlines Key Corporate Goals
December 26, 2018
TRACON Pharmaceuticals Presents Positive Top-Line Clinical Data From Dose Escalation Portion Of Phase 1 Trial Of TRC105 And Opdivo® For Treatment Of Non-Small Cell Lung Cancer
December 21, 2018
TRACON Pharmaceuticals Announces Top-Line Data From Phase 2 TRAXAR Clinical Trial In Renal Cell Carcinoma
December 07, 2018
ARVINAS PRESENTS PRECLINICAL DATA ON PROTEIN DEGRADER, ARV-471, AT THE 2018 SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS)
December 06, 2018
Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma
December 02, 2018
Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma
December 02, 2018
Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis
November 29, 2018
TRACON Pharmaceuticals And I-Mab Biopharma Announce Strategic Partnerships For Multiple Immuno-Oncology Programs
November 28, 2018
Kura Oncology Announces New Patent for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
November 15, 2018
Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy
November 09, 2018
Neon Therapeutics Presents Updated Data at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
November 08, 2018
Kura Oncology Adds Commercial Veteran Mary Szela to Board of Directors
November 08, 2018
Neon Therapeutics Appoints Industry Veteran Robert Bazemore to its Board of Directors
November 01, 2018
Kura Oncology Announces Upcoming Presentations at ASH Annual Meeting
October 23, 2018
IDEAYA Licenses Phase 1 Compound LXS196 For The Treatment Of Cancers With GNAQ And GNA11 Mutations
October 22, 2018
Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC
October 16, 2018
REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets
October 09, 2018
REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors
October 06, 2018
Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers
October 03, 2018
Neon Therapeutics to Present Data from Ongoing Phase 1b NT-001 Clinical Trial at the European Society for Medical Oncology 2018 Congress
October 01, 2018
Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782, a Highly Selective ALK2 Inhibitor, for the Treatment of Patients with Fibrodysplasia Ossificans Progressiva
September 26, 2018
Blueprint Medicines Announces Proof-of-Concept Data Showing Combination of BLU-667 and Osimertinib Overcame Treatment Resistance in Two Patients with EGFR-Mutant, Non-Small Cell Lung Cancer and an Acquired RET Fusion
September 26, 2018
ARVINAS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
September 10, 2018
TRACON Pharmaceuticals Announces Publication Of Phase 1b Results For TRC105 In Combination With Inlyta® In Patients With Advanced Or Metastatic RCC
August 21, 2018
Neon Therapeutics Appoints Jolie M. Siegel as General Counsel
August 08, 2018
TRACON Pharmaceuticals Reports Second Quarter 2018 Financial Results And Provides Corporate Update
August 06, 2018
Neon Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights
August 06, 2018
Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 01, 2018
TRACON To Report Second Quarter 2018 Company Highlights And Financial Results On August 8, 2018
August 01, 2018
Blueprint Medicines to Present at Upcoming Investor Conferences in August
August 01, 2018
Blueprint Medicines Reports Second Quarter 2018 Financial Results
July 31, 2018
Kura Oncology Appoints Marc Grasso, M.D., as Chief Financial Officer and Chief Business Officer
July 30, 2018
Kura Oncology to Report Second Quarter 2018 Financial Results
July 25, 2018
Blueprint Medicines to Report Second Quarter 2018 Financial Results on Wednesday, August 1, 2018
July 18, 2018
Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers
July 02, 2018
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
June 29, 2018
Neon Therapeutics Announces Closing of Initial Public Offering
June 28, 2018
Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock
June 27, 2018
Kura Oncology Announces Commencement of Public Offering of Common Stock
June 26, 2018
Neon Therapeutics Announces Pricing of Initial Public Offering
June 21, 2018
Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced Gastrointestinal Stromal Tumors
June 20, 2018
Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial
June 15, 2018
Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity
June 13, 2018
TRACON Announces Presentation Of Preclinical Data From Studies Of TRC105 In Combination With A PD-1 Antibody In Murine Models Of Colorectal Cancer
June 06, 2018
IDEAYA Biosciences to Present at the 2018 Jefferies Global Healthcare Conference
June 05, 2018
IDEAYA Biosciences Appoints Paul Stone, J.D., as Senior Vice President and General Counsel, Head of Operations and Mark Lackner, Ph.D. as Vice President, Head of Biomarkers and Synthetic Lethal Biology
June 04, 2018
Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
May 30, 2018
TRACON Pharmaceuticals Appoints Biotech Industry Veteran Mark Wiggins As Chief Business Officer
May 22, 2018
OncoDNA announces screening collaboration with Kura Oncology
May 08, 2018
Kura Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 02, 2018
Kura Oncology Announces New Patent for Tipifarnib in Hematologic Malignancies
May 01, 2018
Kura Oncology to Report First Quarter 2018 Financial Results
April 25, 2018
Blueprint Medicines to Report First Quarter 2018 Financial Results on Wednesday, May 2, 2018
April 24, 2018
REVOLUTION Medicines Raises $56 Million in Series B Financing
April 15, 2018
Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors
April 15, 2018
Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667
April 09, 2018
TRACON Pharmaceuticals Announces Closing of Previously Announced Private Placement and Appointment of Ted Wang, Ph.D., of Puissance Capital Management, to Board of Directors
April 09, 2018
Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018
April 04, 2018
Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform
March 25, 2018
ARVINAS ANNOUNCES INITIATION OF PATIENT DOSING IN THE FIRST PHASE 1 CLINICAL TRIAL OF PROTAC™ PROTEIN DEGRADER, ARV-110
March 23, 2018
TRACON Pharmaceuticals Announces $38.7 Million Private Placement
March 15, 2018
IDEAYA Biosciences Raises $94 Million Crossover Series B Financing
March 14, 2018
Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018
March 12, 2018
Kura Oncology Provides Regulatory Update on Tipifarnib and Reports Fourth Quarter and Full Year 2017 Financial Results
March 05, 2018
Kura Oncology to Report Fourth Quarter and Full Year 2017 Financial Results
February 28, 2018
TRACON Pharmaceuticals Reports Fourth Quarter And Year-End 2017 Financial Results And Provides Corporate Update
February 21, 2018
Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results
February 15, 2018
Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
February 14, 2018
Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018
February 12, 2018
Santen Presents Phase I/II Data On DE-122 (Carotuximab) In Patients With Refractory Wet Age-Related Macular Degeneration
December 12, 2017
Neon Therapeutics Expands Board of Directors with Leading Experts in Cancer Drug Discovery and Corporate Finance
December 12, 2017
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
December 11, 2017
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
December 10, 2017
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity
December 07, 2017
Neon Therapeutics Announces Clinical Trial Collaboration with Merck
December 06, 2017
Neon Therapeutics Completes $106 Million Crossover Series B Financing
November 16, 2017
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.
November 10, 2017
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFRα Genotypes
November 06, 2017
STORM Therapeutics Strengthens Board with Appointment of Professor Paul Workman, President and CEO of The Institute of Cancer Research
November 01, 2017
Blueprint Medicines Announces Publication of BLU-285 Translational Data
November 01, 2017
Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis in Plenary Scientific Session at 59th ASH Annual Meeting and Exposition
October 31, 2017
Blueprint Medicines Reports Third Quarter 2017 Financial Results
October 25, 2017
Blueprint Medicines to Report Third Quarter 2017 Financial Results on Tuesday, October 31, 2017
October 04, 2017
Neon Therapeutics Enters License Agreement with the Netherlands Cancer Institute for Neoantigen-based T Cell Therapeutics
July 10, 2017
CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration
June 05, 2017
Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRα D842V Mutation
April 26, 2017
Blueprint Medicines to Report First Quarter 2017 Financial Results on Wednesday, May 3, 2017
April 04, 2017
Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
March 30, 2017
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
March 29, 2017
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
March 27, 2017
Blueprint Medicines to Present on BLU-285 and BLU-554 at Upcoming Scientific Conferences
March 20, 2017
Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667
March 09, 2017
Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results
March 02, 2017
Blueprint Medicines to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, March 9, 2017
December 30, 2016
Biotech Jounce Therapeutics files for a $75 million IPO
December 07, 2016
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
December 06, 2016
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
December 04, 2016
Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis
November 30, 2016
Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors
November 28, 2016
Blueprint Medicines Announces Proof-of-Concept Data from Global Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma
November 15, 2016
Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trials for BLU-285 and BLU-554 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
November 15, 2016
Blueprint Medicines Announces Appointment of Marion Dorsch, Ph.D. as Chief Scientific Officer and the Transition of Christoph Lengauer, Ph.D., MBA, to a Newly Created Executive Vice President Role
September 13, 2016
Oxygen sensing – an essential process for survival
September 07, 2016
Jounce Therapeutics Initiates Phase 1/2 ICONIC Study of JTX2011 in Patients with Advanced Solid Tumors
August 09, 2016
Blueprint Medicines Reports Second Quarter 2016 Financial Results
August 02, 2016
Blueprint Medicines to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016
July 19, 2016
Jounce Therapeutics Announces Major Strategic Collaboration with Celgene Corporation to Develop Next-generation Immuno-oncology Therapies for Patients with Cancer
May 25, 2016
Jounce Therapeutics Appoints Barbara G. Duncan to its Board of Directors
May 10, 2016
Blueprint Medicines Reports First Quarter 2016 Financial Results
May 03, 2016
Blueprint Medicines to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016
April 29, 2016
Eminent cancer researchers elected to Royal Society Fellowship
April 25, 2016
MolecularMD has obtained CE Marking of a Diagnostic Assay Developed for a Daiichi Sankyo, Inc. Phase II Clinical Trial
April 17, 2016
Jounce Therapeutics Presents Data Highlighting Advances From Two Programs in its Immuno-Oncology Pipeline at the 2016 AACR Annual Meeting
March 21, 2016
TRACON Pharmaceuticals Reports Updated Positive Data on Ongoing Complete Response in Choriocarcinoma Patient Treated with TRC105
March 17, 2016
Jounce Therapeutics to Present Program Updates at AACR Annual Meeting 2016
March 15, 2016
Blueprint Medicines Announces Worldwide Collaboration to Accelerate and Expand its Development of Novel Medicines in the Field of Cancer Immunotherapy
March 11, 2016
Blueprint Medicines Reports Fourth Quarter and Full Year 2015 Financial Results
January 27, 2016
TRACON Pharmaceuticals Announces Initiation of TRC102 Phase 2 Clinical Trial in Glioblastoma
January 21, 2016
Jounce Therapeutics Appoints Perry Karsen to its Board of Directors
January 11, 2016
ImaginAb Appoints Benjamin Chen, Ph.D., as CEO, Joseph Limber as Chairman, and Forms Medical Advisory Board
January 05, 2016
Blueprint Medicines Strengthens Executive Leadership Team
December 17, 2015
Blueprint Medicines Added to NASDAQ Biotechnology Index
November 09, 2015
Blueprint Medicines Reports Third Quarter 2015 Financial Results
November 09, 2015
Blueprint Medicines Highlights Advances in Preclinical Discovery Efforts
November 09, 2015
Nextech Invest Portfolio Company Kura Oncology completes Public Offering at NASDAQ
November 07, 2015
Data from MacroGenics’ Ongoing Phase 1 Study of Enoblituzumab (MGA271) Presented at 30th Annual SITC Meeting 2015
November 03, 2015
Jounce Therapeutics Appoints Elizabeth Trehu, M.D., to Chief Medical Officer
October 22, 2015
MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA(R) (pembrolizumab) for Advanced Gastric Cancer
October 12, 2015
Impacting Cancer
September 15, 2015
Jounce Therapeutics Appoints Kim Drapkin, CPA as Chief Financial Officer
September 10, 2015
Blueprint Medicines Receives FDA Authorization to Advance Novel Drug Candidate into Clinical Trial for Systemic Mastocytosis
September 01, 2015
Blueprint Medicines to Present Preclinical Data on BLU-554 and on Novel Drug Target at International Liver Cancer Association 9th Annual Conference
August 10, 2015
Blueprint Medicines Reports Second Quarter 2015 Financial Results and Provides Business Update
August 05, 2015
MacroGenics Provides Update on Corporate Progress and Second Quarter 2015 Financial Results
July 14, 2015
MacroGenics Announces Pricing of Public Offering of Common Stock
July 13, 2015
Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for Two Drug Candidates
June 22, 2015
Blueprint Medicines Debuts Preclinical Data for First-in-Class RET Drug Candidate
May 30, 2015
MacroGenics Presents Updated Data from Phase 1 Study of Margetuximab at ASCO Annual Meeting 2015
May 14, 2015
TRACON’s TRC105 Receives FDA Fast Track Designation
April 30, 2015
Nextech Invest Portfolio Company Blueprint Medicines Raises US$ 147 million in Upsized IPO on NASDAQ
April 25, 2015
TetraLogic Announces Publication of Two Papers Describing Birinapant’s Preclinical Activity in Chronic Hepatitis B
April 24, 2015
Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma
April 23, 2015
Jounce Therapeutics Secures $56 Million in Oversubscribed Series B Financing
April 21, 2015
Peloton Therapeutics Inc. Presents Promising Data on First Inhibitor of HIF-2α for Renal Cell Carcinoma at 2015 AACR Annual Meeting
April 19, 2015
Presentation Abstract
April 19, 2015
Blueprint Medicines Presents New Preclinical Data Demonstrating Significant AntiTumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets
March 24, 2015
Blueprint Medicines Files Registration Statement for Proposed Initial Public Offering
March 03, 2015
Blueprint Medicines Announces Strategic Collaboration with Alexion to Advance Kinase Drug Candidates in Rare Genetic Disease
February 12, 2015
Blueprint Medicines Appoints Anthony Boral, M.D., Ph.D., as Senior Vice President, Clinical Development
January 29, 2015
TRACON Pharmaceuticals Announces Pricing of Initial Public Offering
December 30, 2014
Cancer biotech TRACON Pharmaceuticals files for a $58 million IPO
December 22, 2014
MacroGenics Enters Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies
December 08, 2014
Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for Patients with Systemic Mastocytosis at 2014 American Society of Hematology Annual Meeting
December 01, 2014
TRACON Pharmaceuticals Initiates Randomized Phase 2 Clinical Trial of TRC105 in Patients with Renal Cell Carcinoma
November 24, 2014
Professor Paul Workman has been appointed as Chief Executive and President of The Institute of Cancer Research, London, on a permanent basis.
November 20, 2014
Blueprint Medicines Unveils New Drug Discovery Program for Patients with RET Fusions at 26th EORTC-NCI-AACR Symposium
November 12, 2014
Blueprint Medicines Secures $50 Million in Series C Financing
October 14, 2014
Nextech Invest Announces First Closing of Oncology Fund IV
October 06, 2014
Sunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia
September 29, 2014
MacroGenics and Takeda Enter Second Strategic Alliance to Develop Multiple Additional DART Therapeutics
September 24, 2014
TRACON Pharmaceuticals Announces Results From Clinical Trials of TRC105 in Patients With Ovarian Cancer to be Presented at the 2014 Annual Meeting of the European Society for Medical Oncology
September 22, 2014
TRACON Pharmaceuticals Completes $27 Million Financing and Expands Management Team and Board of Directors
September 19, 2014
First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines
September 10, 2014
Blueprint Medicines Discovers Novel Cancer Drug Targets
September 08, 2014
Blueprint Medicines Presents Positive Data on BLU-554 for Hepatocellular Carcinoma
September 04, 2014
TRACON Pharmaceuticals Initiates Phase 2 Clinical Trial of TRC105 in Patients with Soft Tissue Sarcoma
July 24, 2014
Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer
June 28, 2014
Onkologie verspricht viele Chancen
June 09, 2014
TetraLogic Pharmaceuticals Announces Preclinical Data Indicating Birinapant’s Breadth of Activity in Models of Infectious Disease
May 27, 2014
MacroGenics and Takeda Enter Strategic Alliance to Develop DART for Treatment of Autoimmune Disorders
May 19, 2014
ImaginAb Selected as a Red Herring Top 100 North America Winner
May 06, 2014
MacroGenics Provides Update on Corporate Progress and First Quarter 2014 Financial Results
April 01, 2014
TetraLogic Pharmaceuticals Announces Publication of Preclinical Characterization of Birinapant
March 27, 2014
TetraLogic Pharmaceuticals to Present Data From Its SMAC-Mimetic Program at Upcoming AACR Annual Meeting 2014
March 24, 2014
Blueprint Medicines to Present on the First Isoform Selective FGFR4 Inhibitor at the AACR Annual Meeting 2014
March 24, 2014
Former CEO of Centrum Bank strengthens Nextech Invest’s global growth initiative
March 04, 2014
TRACON Pharmaceuticals Announces Agreement with Santen Pharmaceutical Co., Ltd. for the Development and Commercialization of TRC105 in Ophthalmology
February 27, 2014
Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants
February 20, 2014
MolecularMD to Develop Highly Sensitive Companion Diagnostic Test to Support CML Treatment Free Remission Clinical Trials
February 12, 2014
MacroGenics Completes Follow-on Offering of Common Stock ,Proceeds to fund clinical development of multiple assets
February 05, 2014
Professor Paul Workman receives prestigious Raymond Bourgine Award for cancer research
January 22, 2014
A Rising Biotech Market Offers Great Opportunities
January 07, 2014
Blueprint Medicines Announces $25 Million Series B Financing
December 12, 2013
TetraLogic Announces Pricing of Initial Public Offering of Common Stock
October 14, 2013
Nextech Invest Portfolio Company MacroGenics Starts Trading on NASDAQ
October 10, 2013
Nextech Invest Portfolio Company MacroGenics Starts Trading on NASDAQ
September 24, 2013
MacroGenics – 2013 Fierce 15
September 23, 2013
Fachkompetenz in der Onkologie
September 05, 2013
MacroGenics files paperwork for $60 million IPO
September 05, 2013
German Biotechnology: Where’s the Love?
August 20, 2013
MacroGenics to Receive $10 Million Milestone Payment from Servier for Dosing the First Patient in a Phase 1 Dose Expansion Trial of MGA271
August 12, 2013
MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
July 29, 2013
Cancer Research UK prize winners announced
June 13, 2013
Data and Safety Monitoring Board Recommends Continuation of Sunesis Pharmaceuticals’ VALOR Trial With no Change to Study Conduct
April 16, 2013
Molecular imaging as a de-risking tool: coming into focus?
April 07, 2013
Cancer Immunology Research
March 11, 2013
Innovative startups 2012
January 05, 2013
MacroGenics and Gilead Sciences Enter Strategic Alliance to Develop and Commercialize Four DART™ Products